Story

Spruce Biosciences Stock Gains on Analyst Confidence, Positive FDA Update

ENTHMSVIIDZHZH-TWJAKOHI
Aug 27, 20261 min read
Spruce Biosciences Stock Gains on Analyst Confidence, Positive FDA Update
Text size
Background

Spruce Biosciences (NASDAQ:SPRB) shares rose more than 4% in pre-market trading after H.C. Wainwright reiterated its Buy rating on the stock, citing positive regulatory progress for the company's lead drug candidate.

Analyst Cites Positive FDA Feedback

H.C. Wainwright reaffirmed its Buy rating and $150 price target for Spruce Biosciences, according to a report from Investing.com. The firm's confidence is rooted in the company's completion of two constructive pre-Biologics License Application (BLA) meetings with the U.S. Food and Drug Administration (FDA).

The meetings concerned tralesinidase alfa (TA-ERT), an enzyme replacement therapy being developed for Sanfilippo Syndrome Type B. According to the source, the FDA signaled that Spruce's analytical strategies for the drug were "reasonable," a meaningful regulatory endorsement ahead of a planned BLA submission in the fourth quarter of 2026.

Broader Context and Market Support

The analyst note adds to a generally bullish sentiment for the company. The consensus rating among analysts covering Spruce is a Strong Buy, with price targets reportedly spanning from $104 to $230.

Sample IUX Markets – In-articleAd

This reaffirmation follows a $5.5 million strategic investment announced earlier in the month from the Cure Sanfilippo Foundation and the National MPS Society. The stock's move was also supported by a broader risk-on market tone, with the Nasdaq Composite and S&P 500 both trading higher, which tends to benefit small-cap biotechnology firms.

What This Means for Investors

Shares of Spruce Biosciences are known for high volatility, with a 52-week trading range of $7 to $240. This makes the stock particularly sensitive to news related to its clinical and regulatory milestones.

For investors, the combination of positive FDA feedback and renewed analyst confidence reinforces the timeline for the Q4 2026 BLA filing. This submission is widely seen as a potentially transformative catalyst for the company.

Read next

More on Stocks
Back to latest news

LATEST